Element Biosciences unveiled a new throughput-based option for its AVITI System that it said provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase.
Photo: Molly He, Element CEO and co-founder
For single cell sequencing, the new model offers potential costs as low as $0.60 per million reads, with sequencing runs finishing in less than 24 hours.
“Our goal is to enable labs everywhere to produce high-quality data at the lowest cost,” said Molly He, Element CEO and co-founder, in a presentation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. “Making a $200 genome available on benchtop systems today is an important milestone in that mission.”
Element’s AVITI is available today, subject to volume purchase requirements and other terms and conditions. Customers with existing high throughput can take advantage of volume-based prices to bring costs even lower. Customers who anticipate future growth can buy only the instrumentation they need now, while establishing a stepwise path to $200 genomes as they expand over time, without the need for disruptive equipment changes.
“AVITI was built to lead a movement to increase the access of high-quality sequencing and offer the freedom of genomics science studies without waiting to batch samples,” said Michael Previte, Element Chief Technology Officer, senior vice president of R&D, and co-founder. “While we are only at the beginning of our innovation cycle, AVITI is the only ubiquitous sequencing solution on the market today that delivers the unrivaled combination of cost, quality, turnaround time and long-read solutions.”
Author: Rare Daily Staff
Stay Connected
Sign up for updates straight to your inbox.